vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Flywire Corp (FLYW). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $157.5M, roughly 1.2× Flywire Corp). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 34.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 17.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Flywire Corp is a global payment and receivables solutions provider serving core verticals including education, healthcare, travel, and B2B commerce. It offers secure cross-border payment processing, currency conversion, and workflow tools for organizations and payers worldwide.
AXSM vs FLYW — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $157.5M |
| Net Profit | — | $33.0K |
| Gross Margin | — | — |
| Operating Margin | -33.1% | -0.6% |
| Net Margin | — | 0.0% |
| Revenue YoY | 57.4% | 34.0% |
| Net Profit YoY | — | 100.2% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $157.5M | ||
| Q3 25 | $171.0M | $200.1M | ||
| Q2 25 | $150.0M | $131.9M | ||
| Q1 25 | $121.5M | $133.5M | ||
| Q4 24 | $118.8M | $117.5M | ||
| Q3 24 | $104.8M | $156.8M | ||
| Q2 24 | $87.2M | $103.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $33.0K | ||
| Q3 25 | $-47.2M | $29.6M | ||
| Q2 25 | $-48.0M | $-12.0M | ||
| Q1 25 | $-59.4M | $-4.2M | ||
| Q4 24 | $-74.9M | $-15.9M | ||
| Q3 24 | $-64.6M | $38.9M | ||
| Q2 24 | $-79.3M | $-13.9M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -0.6% | ||
| Q3 25 | -27.0% | 16.1% | ||
| Q2 25 | -24.5% | -6.8% | ||
| Q1 25 | -46.9% | -8.2% | ||
| Q4 24 | -61.1% | -4.9% | ||
| Q3 24 | -59.8% | 12.9% | ||
| Q2 24 | -89.5% | -15.2% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 0.0% | ||
| Q3 25 | -27.6% | 14.8% | ||
| Q2 25 | -32.0% | -9.1% | ||
| Q1 25 | -48.9% | -3.1% | ||
| Q4 24 | -63.1% | -13.5% | ||
| Q3 24 | -61.7% | 24.8% | ||
| Q2 24 | -91.0% | -13.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.01 | ||
| Q3 25 | $-0.94 | $0.23 | ||
| Q2 25 | $-0.97 | $-0.10 | ||
| Q1 25 | $-1.22 | $-0.03 | ||
| Q4 24 | $-1.54 | $-0.12 | ||
| Q3 24 | $-1.34 | $0.30 | ||
| Q2 24 | $-1.67 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $355.0M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $835.2M |
| Total Assets | $713.6M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $355.0M | ||
| Q3 25 | $325.3M | $377.3M | ||
| Q2 25 | $303.0M | $274.2M | ||
| Q1 25 | $300.9M | $255.3M | ||
| Q4 24 | $315.4M | $611.1M | ||
| Q3 24 | $327.3M | $681.1M | ||
| Q2 24 | $315.7M | $571.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $15.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $835.2M | ||
| Q3 25 | $73.7M | $829.1M | ||
| Q2 25 | $73.1M | $792.4M | ||
| Q1 25 | $53.2M | $784.3M | ||
| Q4 24 | $57.0M | $814.8M | ||
| Q3 24 | $92.9M | $843.2M | ||
| Q2 24 | $102.9M | $802.6M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.3B | ||
| Q3 25 | $669.3M | $1.3B | ||
| Q2 25 | $639.8M | $1.1B | ||
| Q1 25 | $596.7M | $1.1B | ||
| Q4 24 | $568.5M | $1.1B | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $998.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $4.9M |
| Free Cash FlowOCF − Capex | — | $4.5M |
| FCF MarginFCF / Revenue | — | 2.9% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 148.06× |
| TTM Free Cash FlowTrailing 4 quarters | — | $98.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $4.9M | ||
| Q3 25 | $1.0M | $150.1M | ||
| Q2 25 | $-32.4M | $24.1M | ||
| Q1 25 | $-43.4M | $-78.9M | ||
| Q4 24 | $-26.2M | $-28.6M | ||
| Q3 24 | $-18.6M | $184.6M | ||
| Q2 24 | $-30.1M | $-19.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $4.5M | ||
| Q3 25 | $988.0K | $149.9M | ||
| Q2 25 | $-32.4M | $23.5M | ||
| Q1 25 | $-43.7M | $-79.1M | ||
| Q4 24 | $-26.2M | $-28.7M | ||
| Q3 24 | $-18.7M | $184.4M | ||
| Q2 24 | $-30.2M | $-19.7M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 2.9% | ||
| Q3 25 | 0.6% | 74.9% | ||
| Q2 25 | -21.6% | 17.8% | ||
| Q1 25 | -36.0% | -59.3% | ||
| Q4 24 | -22.1% | -24.4% | ||
| Q3 24 | -17.9% | 117.6% | ||
| Q2 24 | -34.6% | -19.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 148.06× | ||
| Q3 25 | — | 5.07× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.75× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
FLYW
| Transactions | $126.4M | 80% |
| Platform And Other Revenues | $31.1M | 20% |
